ICD10BillableValid for clinical use

ICD-10 Code E88.11: Partial lipodystrophy

E88.11 is a billable ICD-10 diagnosis code used to classify Partial lipodystrophy in medical records and claims. You may see this code in hospital records, discharge summaries, insurance claims, encounter documentation, referrals, or other healthcare billing and coding records. ICD-10 codes are diagnosis classification codes used in healthcare records, reporting, coding workflows, and billing support. This code sits within the broader ICD-10 area for Endocrine, nutritional and metabolic diseases (E00-E89).

What is this code?

ICD-10 codes are diagnosis classification codes used in healthcare records, reporting, coding workflows, and billing support. This code sits within the broader ICD-10 area for Endocrine, nutritional and metabolic diseases (E00-E89).

šŸ“‹Clinical overview

This code records partial lipodystrophy, a classification that includes acquired and familial contexts. Partial describes the distribution category; it does not name a gene, establish inheritance or show which areas are affected in a particular person. The stored acquired partial, Barraquer-Simons and familial partial inclusions remain distinct clinical contexts rather than one interchangeable mechanism. The title also does not supply a kidney finding, metabolic result or treatment plan. Understanding the entry requires the actual history and assessment, with its original notes, Index routes and qualified associations retained.

When is it used?

  • May be used when a clinician documents partial lipodystrophy in a patient's medical record.
  • May appear in hospital records, claims, referrals, and clinical documentation.
  • This code can be used as a clinically usable diagnosis entry in standardized coding workflows.

What it does not mean

  • A code alone does not explain severity, treatment plan, or outcome.
  • A medical code should not be treated as a substitute for a doctor's diagnosis or advice.

🩺Clinical context

When commonly used
  • The word partial should not be read as a severity grade or reassurance that the condition is a minor cosmetic change. It is also not the same as a single localized injection-site example. The inclusion of both acquired and familial forms means the code alone cannot decide between them. Ask which context the clinician documented and which details remain uncertain. A family member's condition, a clinical-source example or a parent-level genetic association cannot establish the reader's own diagnosis, inheritance pattern or gene.
  • The NLM familial-partial resource describes variable distribution and more than one genetic cause; a genetic cause is not identified in every case. GARD separately describes the acquired Barraquer-Simons context, including possible associated kidney or autoimmune concerns. These resources explain why acquired and familial histories should not be collapsed into one explanation. They do not establish a specific body pattern, gene, kidney condition, autoimmune disease or metabolic abnormality in an individual simply because the recorded code is partial lipodystrophy.
  • The local inclusions are Acquired partial lipodystrophy (APL), Barraquer-Simons lipodystrophy and Familial partial lipodystrophy (FPLD). The local code-first, additional-code and exclusion arrays remain empty; the E88 and E88.1 ancestor notes keep their separate scopes. A broadly related clinical term or an inherited parent mapping is not a new local instruction. Questions about the documented subtype or final coding belong with the clinical and coding teams, not an automatic rewrite based on a general genetics page.
  • The original E88.1 parent and neighboring entries provide classification navigation, not a collection of extra conditions. Six SNOMED relationships belong to the parent, with their original directions, source snapshot and additional-code or external-cause qualifiers. They do not establish an AKT2- or CIDEC-related disorder, a laminopathy, an acquired cause or a congenital condition on this leaf. Shared chapter excerpts concerning diabetes, pregnancy or obesity also do not diagnose those conditions in a reader. Keep navigation, qualified associations and the personal clinical account distinct.
Common workup
  • A useful discussion distinguishes the actual distribution and timing of changes from the examples in a general reference. Ask what supports the clinician's acquired or familial interpretation, whether relevant earlier records are available and what questions remain open. Family history, medicines and existing health findings can be discussed in their real setting, without treating them as facts inferred by this code. The page does not establish an affected region, prior viral illness, pattern of progression or examination result, and it cannot diagnose a relative.
  • Clarify the clinical question behind any proposed investigation and whether it relates to the person's documented findings. A familial-condition reference is not an instruction to order a gene panel for every partial entry. Likewise, GARD's discussion of possible kidney associations does not diagnose kidney disease or prescribe a renal testing schedule. The ECG and facial-filler associations retained on this page are not a partial-lipodystrophy workup. Ask how actual findings, rather than the presence of a related service, would influence further assessment.
  • This leaf retains G0429, three routine ECG associations, Q2026 and Q2028 in their original order and article contexts. The ECG rows distinguish tracing, interpretation/report and the combined service; they are not findings or a compulsory workup. G0429's facial/antiretroviral example does not establish facial involvement or treatment exposure in an individual. Q2026 describes RADIESSE in a 0.1 ML billing unit, and Q2028 describes SCULPTRA in a 0.5 MG unit. Those literal units are not administered doses, a product choice or proof of eligibility or current coverage.
  • When reviewing an existing report or proposed assessment, ask what was actually observed, what question remains open and who will explain the result. A code title, inclusion example or service description is not the result of that assessment. Missing information is not automatically a normal finding, and the absence of a particular related link does not establish that an investigation is unnecessary. The page cannot provide a diagnostic checklist for every subtype or a universal schedule; the clinical reason and documented context should remain visible.
Common management context
  • The acquired and familial contexts may raise different questions for the treating team, so a single code should not be treated as a common treatment pathway. Ask which documented issue a proposed measure addresses and how its suitability will be assessed. A general association with diabetes or other metabolic problems does not establish a need for a glucose-lowering or lipid-lowering medicine. Nor does the inclusion of a facial-filler service prove a cosmetic indication. This page cannot choose replacement therapy, a drug, a procedure, dietary targets or a treatment schedule.
  • Ask who coordinates review of the actual partial-lipodystrophy context and explains any outstanding results. If the acquired-versus-familial distinction is unresolved, keep that uncertainty visible rather than filling it with an assumed gene or family history. The code does not predict progression, complications in relatives or a response to treatment. Follow the responsible team's individualized instructions and discuss new concerns with them; a general resource's possible features are not a checklist of conditions already established in the record.
  • An educational code page cannot determine the cause or urgency of a new health concern. Discuss a changing concern with the responsible clinical team and use the personal safety instructions they have provided; do not wait for a code or terminology question to be settled if medical attention is needed. This explanation does not replace assessment, establish that a symptom is harmless or supply a home rule for excluding another problem. Existing prescribed medicines and any changes to them require the appropriate treating team.
  • A useful shared discussion separates the documented problem, the goal of a proposed measure, the evidence applicable to that person and the arrangements for review. Ask which uncertainties remain and what alternatives need consideration. Neither an entry in this classification branch nor a historical research result selects a medicine, a dose, a dietary target, a genetic test, a cosmetic injection or an operation. No service association guarantees access, reimbursement or benefit, and no general reference promises a particular recovery or treatment response.

šŸ”Key distinctions

Important notes
  • The subtype distinctions do not establish a cause, gene, affected region, severity or an individual result. Partial and generalized contexts include both inherited and acquired examples; localized injection examples do not establish exposure. The grouping parent remains unchanged.
  • HIV-associated coding retains its code-first note and conditional adverse-effect wording. Those notes do not establish a drug cause, and a displayed incomplete stem is not a final encounter code. Parent notes and clinical-source terminology do not become extra diagnoses or silent repairs.
  • Qualified ECG and facial-filler associations remain billing context, not a prescribed workup, procedure performed, product indication, administered dose, eligibility or present coverage. Relevant references are selected separately for each leaf; no shared treatment pathway is assigned.
  • Nine exact stored Index routes remain, including APL, the partial acquired/familial route, progressive lipodystrophy and the named Barraquer or Simons routes. Their original wording, order and hierarchy are not replaced by clinical-source terminology. These classification routes do not prove a particular inheritance pattern, affected body region or association in the reader. The separate other-lipodystrophy entry is not silently treated as equivalent, and no Index route is copied across neighboring pages.
  • The familial-partial NLM page was updated in August 2026. The viewed GARD summary does not provide a revision date in the selected body, so none is invented from a crawl date. NIDDK's selected research account is from April 2015, and the CMS conventions are historical FY2026 material. These sources have different purposes and ages; they are not a newly reviewed comprehensive guideline or individual clinical signoff.
  • All original notes, exclusions, inclusion terms, Index arrays, hierarchy, synonyms, URLs, source metadata, priorities, review flags, specialists, overrides, semantic caches and qualified service relationships remain available in their original places. This educational addition removes none of them and does not silently repair terminology, relationships or coding data. Reference selection is specific to the leaf: inherited, acquired, injection-related and HIV-associated examples are not presented as one common disease mechanism or treatment pathway. This is not individual clinical signoff or a current payment decision.
Related codes to consider
E88.10Lipodystrophy, unspecified
Existing lipodystrophy siblings retain classification context, not interchangeable causes, new diagnoses, hereditary findings, investigation orders or treatment eligibility.
E88.12Generalized lipodystrophy
Existing lipodystrophy siblings retain classification context, not interchangeable causes, new diagnoses, hereditary findings, investigation orders or treatment eligibility.
E88.13Localized lipodystrophy
Existing lipodystrophy siblings retain classification context, not interchangeable causes, new diagnoses, hereditary findings, investigation orders or treatment eligibility.
E88.14HIV-associated lipodystrophy
Existing lipodystrophy siblings retain classification context, not interchangeable causes, new diagnoses, hereditary findings, investigation orders or treatment eligibility.

Code hierarchy

chapter
4Endocrine, nutritional and metabolic diseases (E00-E89)
block
E70-E88Metabolic disorders
category
E88Other and unspecified metabolic disorders
category
E88.1Lipodystrophy, not elsewhere classified
currentE88.1

Official coding notes

Inclusion terms
  • Acquired partial lipodystrophy (APL)
  • Barraquer-Simons lipodystrophy
  • Familial partial lipodystrophy (FPLD)

Where you may see this code

You may see this code in hospital records, discharge summaries, insurance claims, encounter documentation, referrals, or other healthcare billing and coding records.

Related specialists

EndocrinologistGeneral Physician

Coding guidelines

Common synonyms

Partial lipodystrophy

Frequently asked questions

Code details

CodeE88.11
SystemICD10
Display namePartial lipodystrophy
ChapterEndocrine, nutritional and metabolic diseases (E00-E89)
BlockMetabolic disorders

Flags

BillableYes
Valid clinical useYes

Source

SourceICD-10
Version2026-annual
Releaseannual
Year2026

Index terms

Matched terms
APL(acquired partial lipodystrophy)Barraquer(-Simons) disease or syndrome (progressive lipodystrophy)Disease, diseasedDisease, diseasedLipodystrophia progressivaLipodystrophyLipodystrophySimons' disease or syndrome(progressive lipodystrophy)Syndrome

About this content

This page is prepared by HealthAssure's clinical team using official coding standards from ICD-10. AI tools assist with drafting explanations, which are then reviewed and verified by healthcare professionals for accuracy. This content is for informational purposes and does not replace professional medical advice. Meet our team.